Visiongain Report Predicts Dramatic Change for the Japanese Pharma Market

The Japanese pharmaceutical market has entered a period of change that could signify the end of a western dominated world economy. The development of competitive Japanese pharmaceutical companies could drive the recovery of the entire Japanese economy and result in globally significant knock on effects. Japan as a strong far-east manufacturing economy could be the catalyst for China's development, and dramatically alter both US and EU trading streams.

The Japanese pharmaceutical market is the second largest individual pharmaceutical market and is currently valued at $60 billion. However, it has long been a frustrating market for the leading pharmaceutical companies who are unable to generate the revenue and profit levels that the US and EU markets provide. A historically weak economy and biennial mandatory drug price reductions have hampered both domestic and global pharmaceutical companies operating in Japan.

However, change is afoot and this large market appears ready to grow further. Global pharmaceutical companies are moving into the Japanese market with unprecedented strength. The leading Japanese companies have merged themselves into greater financial strength and are stretching away from their smaller competitors. The strategy is simple - dominate the Japanese market through lucrative expansion into the US and EU markets.

The CEO of Pfizer, the world's largest pharmaceutical company, when asked to comment on the potential for growth in Japan has stated in the past that, "A global pharmaceutical industry needs free markets". Changing Japanese regulations aimed at increasing industrial competitiveness, as well as a desperate need for new markets has resulted in the stirring of the Japanese market.

Visiongain's report - Japanese Pharmaceutical Market, 2006-2011 - assess the market, analyses the key companies involved and predicts the changes that are likely to be seen in the next five years in the Japanese pharmaceutical market. Assessment of the regulations governing the market, particularly the system of patents and government reimbursement illuminate a previously frowned upon market, and highlight the potential already seen by the leading pharmaceutical companies.

ENDS

http://www.bioportfolio.com/cgi-bin/acatalog/Japanese_Pharmaceutical_Market__2006-2011.html